Molecular markers in thyroid cytology: diagnostic and prognostic implications

References

• Gharib H, Papini E, Paschke R et al American association of clinical endocrinologists, associazione medici endocrinologi, and european thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr. Pract. 16(3), 468–475 (2010).
   PubMedGoogle Scholar
• Carpi A, Ferrari E, Toni MG, Sagripanti A, Nicolini A, Di Coscio G. Needle aspiration techniques in preoperative selection of patients with thyroid nodules: a long-term study. J. Clin. Oncol. 14(5), 1704–1712 (1996).
   PubMed Web of Science ®Google Scholar
• Cibas ES, Ali SZ. The bethesda system for reporting thyroid cytopathology. Thyroid 19(11), 1159–1165 (2009).
   PubMed Web of Science ®Google Scholar
• Chudova D, Wilde JI, Wang ET et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J. Clin. Endocrinol. Metab. 95(12), 5296–5304 (2010).
   PubMed Web of Science ®Google Scholar
• Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute thyroid fine needle aspiration state of the science conference. Cancer 117(3), 195–202 (2009).
   PubMed Web of Science ®Google Scholar
• Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of ‘follicular lesion of undetermined significance/atypia of undetermined significance’. Cancer Cytopathol. 118(1), 17–23 (2010).
   PubMed Web of Science ®Google Scholar
• Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S. Implications of the proposed thyroid fine-needle aspiration category of “follicular lesion of undetermined significance”: a five-year multi-institutional analysis. Diagn. Cytopathol. 37(10), 710–714 (2009).
   PubMed Web of Science ®Google Scholar
• Duick DS. Overview of molecular biomarkers for enhancing the management of cytologically indeterminate thyroid nodules and thyroid cancer. Endocr. Pract. 18(4), 611–615 (2012).
   PubMed Web of Science ®Google Scholar
• Kim MI, Alexander EK. Diagnostic use of molecular markers in the evaluation of thyroid nodules. Endocr. Pract. 18(5), 796–802 (2012).
   PubMed Web of Science ®Google Scholar
• Saggiorato E, De Pompa R, Volante M et al. Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr. Relat. Cancer 12(2), 305–317 (2005).
   PubMed Web of Science ®Google Scholar
• de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn. Pathol. 7, 97 (2012).
   PubMed Web of Science ®Google Scholar
• Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. Apmis 120(5), 368–379 (2012).
   PubMed Web of Science ®Google Scholar
• Chiu CG, Strugnell SS, Griffith OL et al. Diagnostic utility of galectin-3 in thyroid cancer. Am. J. Pathol. 176(5), 2067–2081 (2010).
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, Orlandi F, Saggiorato E et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 9(6), 543–549 (2008).
   PubMed Web of Science ®Google Scholar
• Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod. Pathol. 18(1), 48–57 (2005).
   PubMed Web of Science ®Google Scholar
• de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47(4), 391–401 (2005).
   PubMed Web of Science ®Google Scholar
• Yousaf U, Christensen LH, Rasmussen AK et al. Immunohistochemical staining for thyroid peroxidase (TPO) of needle core biopsies in the diagnosis of scintigraphically cold thyroid nodules. Clin. Endocrinol. 68(6), 996–1001 (2008).
   PubMed Web of Science ®Google Scholar
• de Micco C, Savchenko V, Giorgi R, Sebag F, Henry JF. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br. J. Cancer 98(4), 818–823 (2008).
   PubMed Web of Science ®Google Scholar
• Cochand-Priollet B, Prat JJ, Polivka M et al. Thyroid fine needle aspiration: the morphological features on thinprep slide preparations. Eighty cases with histological control. Cytopathology 14(6), 343–349 (2003).
   PubMed Web of Science ®Google Scholar
• Fadda G, Rossi ED. Liquid-based cytology in fine-needle aspiration biopsies of the thyroid gland. Acta Cytol. 55(5), 389–400 (2011).
   PubMed Web of Science ®Google Scholar
• Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr. Rev. 34(3), 439–455 (2013).
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7(10), 569–580 (2011).
   PubMed Web of Science ®Google Scholar
• Yip L, Nikiforova MN, Carty SE et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146(6), 1215–1223 (2009).
   PubMed Web of Science ®Google Scholar
• O'Neill CJ, Bullock M, Chou A et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148(6), 1139–1145, discussion 1145–1136 (2010).
   PubMed Web of Science ®Google Scholar
• Fukahori M, Yoshida A, Hayashi H et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 22(7), 683–689 (2012).
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. metab. 94(6), 2092–2098 (2009).
   PubMed Web of Science ®Google Scholar
• Rossi ED, Martini M, Capodimonti S et al. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur. J. Endocrinol. 168(6), 853–859 (2013).
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Yip L, Nikiforova MN. New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers. Clin. Cancer. Res. 19(9), 2283–2288 (2013).
   PubMed Web of Science ®Google Scholar
• Alzahrani AS, Xing M. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr.Relat. Cancer 20(1), 13–22 (2013).
   PubMed Web of Science ®Google Scholar
• Yip L, Farris C, Kabaker AS et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J. Clin. Endocrinol. Metab. 97(6), 1905–1912 (2012).
   PubMed Web of Science ®Google Scholar
• Hodak SP, Rosenthal For The American Thyroid Association Clinical Affairs Committee DS. Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid 23(2), 131–134 (2013).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J. Clin. Endocrinol. Metab. 98(7), 2811–2821 (2013).
   PubMed Web of Science ®Google Scholar
• Alexander EK, Kennedy GC, Baloch ZW et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N. Engl. J. Med. 367(8), 705–715 (2012).
   PubMed Web of Science ®Google Scholar
• Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J. Clin. Endocrinol. Metab. 96(11), e1719–e1726 (2011).
   PubMed Web of Science ®Google Scholar
• Milas M, Mazzaglia P, Chia SY et al. The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillance of thyroid cancers. Surgery 141(2), 137–146, discussion 146 (2007).
   PubMed Web of Science ®Google Scholar
• Chia SY, Milas M, Reddy SK et al. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J. Clin. Endocrinol. Metab. 92(2), 468–475 (2007).
   PubMed Web of Science ®Google Scholar
• Wagner K, Arciaga R, Siperstein A et al. Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnostic synergy for detecting thyroid cancer. J. Clin. Endocrinol. Metab. 90(4), 1921–1924 (2005).
   PubMed Web of Science ®Google Scholar
• Milas M, Shin J, Gupta M et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann. Surg. 252(4), 643–651 (2010).
   PubMed Web of Science ®Google Scholar
• Gomez Saez JM. Diagnostic and prognostic markers in differentiated thyroid cancer. Curr. Genomics 12(8), 597–608 (2011).
   PubMed Web of Science ®Google Scholar
• Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(9), 3584–3591 (2006).
   PubMed Web of Science ®Google Scholar
• Sheu SY, Grabellus F, Schwertheim S, Worm K, Broecker-Preuss M, Schmid KW. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br. J. Cancer 102(2), 376–382 (2010).
   PubMed Web of Science ®Google Scholar
• Shen R, Liyanarachchi S, Li W et al. MicroRNA signature in thyroid fine needle aspiration cytology applied to “atypia of undetermined significance” cases. Thyroid 22(1), 9–16 (2012).
   PubMed Web of Science ®Google Scholar
• Kitano M, Rahbari R, Patterson EE et al. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid 22(3), 285–291 (2012).
   PubMed Web of Science ®Google Scholar
• Keutgen XM, Filicori F, Crowley MJ et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin. Cancer Res. 18(7), 2032–2038 (2012).
   PubMed Web of Science ®Google Scholar
• Dettmer M, Vogetseder A, Durso MB et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J. Clin. Endocrinol. Metab. 98(1), e1–e7 (2013).
   PubMed Web of Science ®Google Scholar
• Dettmer MS, Perren A, Komminoth P, Moch H, Nikiforov YE, Nikiforova MN. Micro-RNA expression profiles in follicular variant of papillary thyroid carcinomas. Thyroid. 22 (Suppl. 1), (2012).
   Google Scholar
• Kouniavsky G, Zeiger MA. The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology. J. Surg. Oncol. 105(5), 438–443 (2012).
   PubMed Web of Science ®Google Scholar
• Faquin WC. Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma? Cancer cytopathol. 121(3), 116–119 (2013).
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts & Figures 2012. American Cancer Society, Atlanta, GA, USA (2012).
   Google Scholar